<p>SEI 投资公司在最近向证券交易委员会的披露中表示，在第二季度将其在霍洛吉公司（NASDAQ:HOLX - 免费报告）股票中的持股比例削减了 7.9%。该基金在此期间出售了 118,671 股后，持有霍洛吉的 1,379,476 股股票。截至其最近向证券交易委员会的备案，SEI 投资公司持有霍洛吉约 0.62% 的股份，价值 89,887,000 美元。</p>
<ul>
<li>现在是购买这三家提高收入指引的医疗公司时机吗？</li>
</ul>
<p>其他几家机构投资者和对冲基金最近也增加或减少了在 HOLX 的持股。景顺公司在第二季度将其在霍洛吉的持股增加了 72.5%。景顺公司现在拥有 8,340,785 股霍洛吉的股票，价值 543,486,000 美元，此前在此期间又购买了 3,505,828 股。挪威银行在第二季度购买了霍洛吉的新股份，价值 180,055,000 美元。Allspring 全球投资控股公司在第二季度将其在霍洛吉的持股增加了 473.5%。Allspring 全球投资控股公司现在拥有 1,701,820 股霍洛吉的股票，价值 111,180,000 美元，此前在此期间又收购了 1,405,085 股。Black Creek 投资管理公司在第二季度将其在霍洛吉的持股增加了 26.1%。Black Creek 投资管理公司现在拥有 4,027,829 股霍洛吉的股票，价值 262,453,000 美元，此前在上个季度又收购了 832,444 股。最后，Arrowstreet 资本有限合伙公司在第二季度将其在霍洛吉的持股增加了 28.1%。Arrowstreet 资本有限合伙公司现在拥有 2,767,813 股霍洛吉的股票，价值 180,351,000 美元，此前在此期间又收购了 606,782 股。对冲基金和其他机构投资者持有该公司 94.73% 的股票。</p>
<h2>分析师设定新目标价</h2>
<p>多家研究公司对 HOLX 发布了报告。斯蒂芬斯将霍洛吉的评级从 “增持” 下调至 “持平”，并在 10 月 22 日的研究报告中将该公司的目标价从 78.00 美元下调至 76.00 美元。摩根士丹利在 11 月 11 日的研究报告中将霍洛吉的目标价从 69.00 美元上调至 76.00 美元，并给予该公司 “持平” 评级。BTIG 研究在 10 月 21 日的研究报告中重申了对霍洛吉股票的 “中性” 评级。韦斯评级在 10 月 31 日的报告中重申了对霍洛吉股票的 “持有（c）” 评级。最后，Evercore ISI 在 10 月 7 日的报告中设定了霍洛吉的目标价为 78.00 美元，并给予该股票 “跑赢大盘” 评级。五位分析师对该股票给予了买入评级，十四位分析师对该股票给予了持有评级。根据 MarketBeat.com 的数据，霍洛吉目前的共识评级为 “持有”，平均目标价为 79.29 美元。</p>
<ul>
<li>蝴蝶网络能在 2023 年展翅高飞吗？</li>
</ul>
<p><strong>查看我们对霍洛吉的最新分析</strong></p>
<h2>内部人士下注</h2>
<p>在其他消息中，首席执行官 Stephen P. Macmillan 在 9 月 22 日的交易中出售了 138,358 股公司的股票。该股票以 66.97 美元的平均价格出售，总交易额为 9,265,835.26 美元。交易后，首席执行官在公司中持有 1,234,624 股，价值约 82,682,769.28 美元。这笔交易代表了他们持股比例的 10.08% 的减少。该出售在向 SEC 的备案中披露，相关信息可通过此链接访问。此外，董事 Christiana Stamoulis 在 10 月 20 日的交易中出售了 7,402 股公司的股票。该股票以 73.07 美元的平均价格出售，总交易额为 540,864.14 美元。交易后，该董事直接持有 47,336 股公司股票，价值 3,458,841.52 美元。这笔交易代表了他们持股比例的 13.52% 的减少。该出售的 SEC 备案提供了更多信息。1.88% 的股票目前由公司内部人士持有。</p>
<h2>霍洛吉价格表现</h2>
<p>霍洛吉在周五开盘价为 74.83 美元。该股票的市值为 166.8 亿美元，市盈率为 30.17，PEG 比率为 2.12，贝塔值为 0.70。霍洛吉公司 52 周低点为 51.90 美元，52 周高点为 76.29 美元。该公司的速动比率为 3.06，流动比率为 3.75，债务与股本比率为 0.50。该公司的 50 日移动平均线为 72.88 美元，200 日移动平均线为 68.15 美元。</p>
<p>霍洛吉（NASDAQ:HOLX - 获取免费报告）在 11 月 3 日发布了季度财报。该医疗设备提供商报告季度每股收益为 1.13 美元，超出市场共识预期的 1.10 美元，超出 0.03 美元。该公司季度收入为 10.5 亿美元，而市场共识预期为 10.3 亿美元。霍洛吉的净利润率为 13.80%，股本回报率为 20.13%。该公司的收入较去年同期增长了 6.2%。去年同期，该公司每股收益为 1.01 美元。整体来看，卖方分析师预计霍洛吉将在本年度发布 4.28 美元的每股收益。</p>
<h2>霍洛吉简介</h2>
<p>（免费报告）</p>
<p>豪洛捷公司开发、制造和供应诊断产品、医学影像系统以及用于女性健康的外科产品，旨在通过早期检测和治疗来改善女性健康。该公司通过四个部门运营：诊断、乳腺健康、妇科外科和骨骼健康。它提供 Aptima 分子诊断试剂以检测感染性微生物；Aptima 病毒载量检测用于乙型肝炎病毒、丙型肝炎病毒、人类免疫缺陷病毒和人类巨细胞病毒；Aptima 细菌性阴道病和念珠菌性阴道炎检测用于阴道炎的诊断；Aptima SARS-CoV-2 和 Panther Fusion SARS-CoV-2 检测用于检测 SARS-CoV-2；ThinPrep 系统用于细胞学应用；以及快速胎儿纤维连接蛋白检测，帮助医生评估早产风险。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们认为比豪洛捷更好的股票</li>
<li>经济报告在成功投资策略中的作用</li>
<li>2026 年应避免的三只最近被下调评级的股票</li>
<li>如何计算期权利润</li>
<li>芯片热潮回归：三只有巨大收益潜力的股票</li>
<li>在 52 周高点盈利交易股票</li>
<li>甲骨文股票遭重创：为何其人工智能管道可能推动 2026 年反弹</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SE9MWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SE9MWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在豪洛捷吗？</h2>
<p>在考虑豪洛捷之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛市场注意到之前购买的股票……而豪洛捷并不在名单上。</p>
<p>虽然豪洛捷目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

豪洛捷

SEI投资

<p>SEI 投资公司在第二季度减少了对豪洛捷公司的持股，降幅为 7.9%，目前持有 1,379,476 股，市值为 8,990 万美元。其他投资者也调整了他们的持仓，景顺公司将其持股增加了 72.5%。分析师们给出了混合评级，普遍维持 “持有” 评级，平均目标价为 79.29 美元。首席执行官 Stephen Macmillan 出售了 138,358 股，持股比例下降了 10.08%。豪洛捷的股票开盘价为 74.83 美元，市值为 166.8 亿美元，52 周最高价为 76.29 美元</p>

<p>Sei Investments Co. trimmed its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 7.9% in the 2nd quarter, according to its most recent disclosure with the Securities &amp; Exchange Commission. The fund owned 1,379,476 shares of the medical equipment provider's stock after selling 118,671 shares during the period. Sei Investments Co. owned approximately 0.62% of Hologic worth $89,887,000 as of its most recent filing with the Securities &amp; Exchange Commission.</p>
<div class="lb-trans"><p>SEI 投资公司在最近向证券交易委员会的披露中表示，在第二季度将其在霍洛吉公司（NASDAQ:HOLX - 免费报告）股票中的持股比例削减了 7.9%。该基金在此期间出售了 118,671 股后，持有霍洛吉的 1,379,476 股股票。截至其最近向证券交易委员会的备案，SEI 投资公司持有霍洛吉约 0.62% 的股份，价值 89,887,000 美元。</p>
</div><ul>
<li>Time to buy these 3 healthcare companies that raised revenue guidance?</li>
</ul>
<div class="lb-trans"><ul>
<li>现在是购买这三家提高收入指引的医疗公司时机吗？</li>
</ul>
</div><p>Several other institutional investors and hedge funds also recently added to or reduced their stakes in HOLX. Invesco Ltd. grew its position in Hologic by 72.5% in the 2nd quarter. Invesco Ltd. now owns 8,340,785 shares of the medical equipment provider's stock worth $543,486,000 after purchasing an additional 3,505,828 shares during the period. Norges Bank purchased a new position in shares of Hologic in the 2nd quarter worth $180,055,000. Allspring Global Investments Holdings LLC grew its holdings in shares of Hologic by 473.5% in the second quarter. Allspring Global Investments Holdings LLC now owns 1,701,820 shares of the medical equipment provider's stock worth $111,180,000 after acquiring an additional 1,405,085 shares during the period. Black Creek Investment Management Inc. increased its position in Hologic by 26.1% during the second quarter. Black Creek Investment Management Inc. now owns 4,027,829 shares of the medical equipment provider's stock valued at $262,453,000 after acquiring an additional 832,444 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its holdings in Hologic by 28.1% in the second quarter. Arrowstreet Capital Limited Partnership now owns 2,767,813 shares of the medical equipment provider's stock valued at $180,351,000 after acquiring an additional 606,782 shares during the period. Hedge funds and other institutional investors own 94.73% of the company's stock.</p>
<div class="lb-trans"><p>其他几家机构投资者和对冲基金最近也增加或减少了在 HOLX 的持股。景顺公司在第二季度将其在霍洛吉的持股增加了 72.5%。景顺公司现在拥有 8,340,785 股霍洛吉的股票，价值 543,486,000 美元，此前在此期间又购买了 3,505,828 股。挪威银行在第二季度购买了霍洛吉的新股份，价值 180,055,000 美元。Allspring 全球投资控股公司在第二季度将其在霍洛吉的持股增加了 473.5%。Allspring 全球投资控股公司现在拥有 1,701,820 股霍洛吉的股票，价值 111,180,000 美元，此前在此期间又收购了 1,405,085 股。Black Creek 投资管理公司在第二季度将其在霍洛吉的持股增加了 26.1%。Black Creek 投资管理公司现在拥有 4,027,829 股霍洛吉的股票，价值 262,453,000 美元，此前在上个季度又收购了 832,444 股。最后，Arrowstreet 资本有限合伙公司在第二季度将其在霍洛吉的持股增加了 28.1%。Arrowstreet 资本有限合伙公司现在拥有 2,767,813 股霍洛吉的股票，价值 180,351,000 美元，此前在此期间又收购了 606,782 股。对冲基金和其他机构投资者持有该公司 94.73% 的股票。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>A number of research firms have issued reports on HOLX. Stephens downgraded Hologic from an &#34;overweight&#34; rating to an &#34;equal weight&#34; rating and cut their price target for the company from $78.00 to $76.00 in a research note on Wednesday, October 22nd. Morgan Stanley lifted their price objective on Hologic from $69.00 to $76.00 and gave the company an &#34;equal weight&#34; rating in a research report on Tuesday, November 11th. BTIG Research reiterated a &#34;neutral&#34; rating on shares of Hologic in a research note on Tuesday, October 21st. Weiss Ratings reaffirmed a &#34;hold (c)&#34; rating on shares of Hologic in a report on Friday, October 31st. Finally, Evercore ISI set a $78.00 target price on Hologic and gave the stock an &#34;outperform&#34; rating in a report on Tuesday, October 7th. Five analysts have rated the stock with a Buy rating and fourteen have issued a Hold rating to the stock. According to MarketBeat.com, Hologic presently has a consensus rating of &#34;Hold&#34; and an average target price of $79.29.</p>
<div class="lb-trans"><p>多家研究公司对 HOLX 发布了报告。斯蒂芬斯将霍洛吉的评级从 “增持” 下调至 “持平”，并在 10 月 22 日的研究报告中将该公司的目标价从 78.00 美元下调至 76.00 美元。摩根士丹利在 11 月 11 日的研究报告中将霍洛吉的目标价从 69.00 美元上调至 76.00 美元，并给予该公司 “持平” 评级。BTIG 研究在 10 月 21 日的研究报告中重申了对霍洛吉股票的 “中性” 评级。韦斯评级在 10 月 31 日的报告中重申了对霍洛吉股票的 “持有（c）” 评级。最后，Evercore ISI 在 10 月 7 日的报告中设定了霍洛吉的目标价为 78.00 美元，并给予该股票 “跑赢大盘” 评级。五位分析师对该股票给予了买入评级，十四位分析师对该股票给予了持有评级。根据 MarketBeat.com 的数据，霍洛吉目前的共识评级为 “持有”，平均目标价为 79.29 美元。</p>
</div><ul>
<li>Can Butterfly Network Spread its Wings in 2023?</li>
</ul>
<div class="lb-trans"><ul>
<li>蝴蝶网络能在 2023 年展翅高飞吗？</li>
</ul>
</div><p><strong>Check Out Our Latest Analysis on Hologic</strong></p>
<div class="lb-trans"><p><strong>查看我们对霍洛吉的最新分析</strong></p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other news, CEO Stephen P. Macmillan sold 138,358 shares of the firm's stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the transaction, the chief executive officer owned 1,234,624 shares in the company, valued at approximately $82,682,769.28. This trade represents a 10.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Christiana Stamoulis sold 7,402 shares of the firm's stock in a transaction dated Monday, October 20th. The shares were sold at an average price of $73.07, for a total transaction of $540,864.14. Following the transaction, the director directly owned 47,336 shares in the company, valued at $3,458,841.52. This trade represents a 13.52% decrease in their position. The SEC filing for this sale provides additional information. 1.88% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他消息中，首席执行官 Stephen P. Macmillan 在 9 月 22 日的交易中出售了 138,358 股公司的股票。该股票以 66.97 美元的平均价格出售，总交易额为 9,265,835.26 美元。交易后，首席执行官在公司中持有 1,234,624 股，价值约 82,682,769.28 美元。这笔交易代表了他们持股比例的 10.08% 的减少。该出售在向 SEC 的备案中披露，相关信息可通过此链接访问。此外，董事 Christiana Stamoulis 在 10 月 20 日的交易中出售了 7,402 股公司的股票。该股票以 73.07 美元的平均价格出售，总交易额为 540,864.14 美元。交易后，该董事直接持有 47,336 股公司股票，价值 3,458,841.52 美元。这笔交易代表了他们持股比例的 13.52% 的减少。该出售的 SEC 备案提供了更多信息。1.88% 的股票目前由公司内部人士持有。</p>
</div><h2>Hologic Price Performance</h2>
<div class="lb-trans"><h2>霍洛吉价格表现</h2>
</div><p>HOLX opened at $74.83 on Friday. The stock has a market cap of $16.68 billion, a P/E ratio of 30.17, a PEG ratio of 2.12 and a beta of 0.70. Hologic, Inc. has a 52-week low of $51.90 and a 52-week high of $76.29. The company has a quick ratio of 3.06, a current ratio of 3.75 and a debt-to-equity ratio of 0.50. The business has a fifty day moving average of $72.88 and a 200 day moving average of $68.15.</p>
<div class="lb-trans"><p>霍洛吉在周五开盘价为 74.83 美元。该股票的市值为 166.8 亿美元，市盈率为 30.17，PEG 比率为 2.12，贝塔值为 0.70。霍洛吉公司 52 周低点为 51.90 美元，52 周高点为 76.29 美元。该公司的速动比率为 3.06，流动比率为 3.75，债务与股本比率为 0.50。该公司的 50 日移动平均线为 72.88 美元，200 日移动平均线为 68.15 美元。</p>
</div><p>Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings results on Monday, November 3rd. The medical equipment provider reported $1.13 EPS for the quarter, topping the consensus estimate of $1.10 by $0.03. The company had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $1.03 billion. Hologic had a net margin of 13.80% and a return on equity of 20.13%. The firm's revenue was up 6.2% compared to the same quarter last year. During the same quarter last year, the firm posted $1.01 EPS. As a group, sell-side analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current year.</p>
<div class="lb-trans"><p>霍洛吉（NASDAQ:HOLX - 获取免费报告）在 11 月 3 日发布了季度财报。该医疗设备提供商报告季度每股收益为 1.13 美元，超出市场共识预期的 1.10 美元，超出 0.03 美元。该公司季度收入为 10.5 亿美元，而市场共识预期为 10.3 亿美元。霍洛吉的净利润率为 13.80%，股本回报率为 20.13%。该公司的收入较去年同期增长了 6.2%。去年同期，该公司每股收益为 1.01 美元。整体来看，卖方分析师预计霍洛吉将在本年度发布 4.28 美元的每股收益。</p>
</div><h2>Hologic Profile</h2>
<div class="lb-trans"><h2>霍洛吉简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.</p>
<div class="lb-trans"><p>豪洛捷公司开发、制造和供应诊断产品、医学影像系统以及用于女性健康的外科产品，旨在通过早期检测和治疗来改善女性健康。该公司通过四个部门运营：诊断、乳腺健康、妇科外科和骨骼健康。它提供 Aptima 分子诊断试剂以检测感染性微生物；Aptima 病毒载量检测用于乙型肝炎病毒、丙型肝炎病毒、人类免疫缺陷病毒和人类巨细胞病毒；Aptima 细菌性阴道病和念珠菌性阴道炎检测用于阴道炎的诊断；Aptima SARS-CoV-2 和 Panther Fusion SARS-CoV-2 检测用于检测 SARS-CoV-2；ThinPrep 系统用于细胞学应用；以及快速胎儿纤维连接蛋白检测，帮助医生评估早产风险。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Hologic</li>
<li>The Role Economic Reports Play in a Successful Investment Strategy</li>
<li>3 Recently Downgraded Stocks to Avoid in 2026</li>
<li>How to Calculate Options Profits</li>
<li>The Chip Boom Is Back: 3 Stocks Positioned for Huge Gains</li>
<li>Profitably Trade Stocks at 52-Week Highs</li>
<li>Oracle Stock Hit Hard: Why Its AI Pipeline Could Drive a 2026 Rally</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比豪洛捷更好的股票</li>
<li>经济报告在成功投资策略中的作用</li>
<li>2026 年应避免的三只最近被下调评级的股票</li>
<li>如何计算期权利润</li>
<li>芯片热潮回归：三只有巨大收益潜力的股票</li>
<li>在 52 周高点盈利交易股票</li>
<li>甲骨文股票遭重创：为何其人工智能管道可能推动 2026 年反弹</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SE9MWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=HOLX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Hologic Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在豪洛捷吗？</h2>
</div><p>Before you consider Hologic, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑豪洛捷之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hologic wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛市场注意到之前购买的股票……而豪洛捷并不在名单上。</p>
</div><p>While Hologic currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然豪洛捷目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

SEI 投资公司减少了其在豪洛捷公司$HOLX 的股票持仓